Effect of Orthosiphon stamineus Extract on HIF-1A, Endothelin-1, and VEGFR-2 Gene Expression in NRK-52E Renal Tubular Cells Subjected to Glucotoxicity

Devaprasad Markandeyan¹, Shiek S.S.J. Ahmed², Palani Perumal³*, Arulvasu Chinnasamy⁴, Bhavatariini Govindaraj⁵, Niranjni Sekar⁶, Sudhan Mookandi⁷, Priyadarshini Shanmugam⁸, Janakiraman Velayudam², Deepak Rajasekar Padmanaban⁴ and Perumal Jayaraman⁵

¹Department of Neurology, Faculty of Medicine, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Kelambakkam 603103, Tamil Nadu, India; ²Drug Discovery and Multi-omics Laboratory, Faculty of Allied Health Sciences, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Kelambakkam 603103, Tamil Nadu, India; ³Centre for Advanced Studies in Botany, University of Madras, Guindy Campus, Chennai 600025, Tamil Nadu, India; ⁴Dept. of Zoology, University of Madras, Guindy Campus, Chennai 600025, Tamil Nadu, India; ⁵Department of Microbiology, Faculty of Medicine, Chettinad Hospital and Research Institute, Chettinad Academy of Research and Education, Kelambakkam 603103, Tamil Nadu, India

Introduction

Orthosiphon stamineus Benth. (Lamiaceae) is a perennial medicinal herb cultivated in tropical countries (Shafaei et al., 2017). It has been used to manage diabetes mellitus and its complications, particularly chronic renal failure and diabetic nephropathy (Sun et al., 2014). Various phytochemicals present in Orthosiphon stamineus effectively reverse diabetic complications by acting through various pathogenic pathways. Arjunolic acid is known to reduce the Nuclear Factor Kappa-B (NF-Kb) in glomeruli (Manna and Sil, 2012). Ursolic acid reduces advanced glycosylation end products, tumor necrosis factor-α, and interleukin-1 and increases the expression of superoxide dismutase in cardiac muscle (Wang et al., 2018). Ursolic acid also decreases NF-κB expression of superoxide dismutase in cardiac muscle (Wang et al., 2018). Ursolic acid also decreases NF-κB expression.
kB and Janus kinase (JNK) activity (Xu et al., 2018). In this study, we aim to evaluate the expression of important genes involved in the pathogenesis of diabetic nephropathy. In hyperglycemia, Hypoxia-inducible factor-1α causes apoptosis in renal tubules by inducing Heme oxygenase (HO)-1, a gene (Ferroptosis) (HIF-1α) (Sun et al., 2012; Chiang et al., 2018; Feng et al., 2021; Song et al., 2022). Elevated HIF activity in diabetes is detrimental to renal glomeruli and tubular cells (Rosenberger et al., 2008; Iso et al., 2010; Patrik Persson, 2017). Plasma and urinary Endothelin-1 levels were elevated in patients with diabetic nephropathy and antagonizing ET1 receptors were shown to be beneficial to diabetic kidneys (Peppa-Patrikiou et al., 1998; Wenzelet et al., 1999). A VEGFR2 pathway-activation blockade improved renal function and alleviated glomerular damage in diabetic mice models (Lavoz et al., 2020). GSK-3β plays a detrimental role and contributes to the pathogenesis of diabetic kidney disease, and GSK-3β inhibition can improve kidney function in diabetics (Lin et al., 2006; Paeng et al., 2014; Guo et al., 2016; Pawar et al., 2023; Sarkar et al., 2023; Biswas et al., 2023). Matoba and Keiichiro, (2009) have shown that Rho-kinase inhibition prevents the progression of diabetic nephropathy by downregulating hypoxia-inducible factor 1α. In this experiment, we intend to study the effect of Orthosiphon extract on the gene expression of Endothelin-1, VEGFR-2, and HIF-1 alpha in NRK-52E (rat renal proximal tubular epithelial cell) cells subjected to glucotoxicity and also study the docking properties of the phytochemicals of Orthosiphon on GSK-3β and Rho-kinase, which regulate HIF-1α levels.

Materials and Methods

Plant collection and preparation of crude extract

Fresh and healthy plants of Orthosiphon stamineus were procured from its natural habitat in Siruthavur, Chengalpattu district, Tamil Nadu, India. Fresh leaves were washed and shade-dried for 3 days at room temperature. The dried leaves were powdered into fine particles with the help of a blender (Venus, India) and stored in a sterile airtight container until further use. Fifty grams (50g) of powdered plant sample were extracted with 1000 mL of 99% methanol in a Soxhlet apparatus. The extract was concentrated to dryness using a rotary evaporator. Twenty mg of the concentrated extract was dissolved in 1 ml of dimethyl sulfoxide (DMSO) and used as the stock solution, from which different concentrations were used for the treatment of cell lines.

Cell line and maintenance

NRK-52E cells, obtained from the National Centre for Cell Science in Pune, India, were cultured in Dulbecco’s modified Eagle’s medium (DME). The culture medium was supplemented with 10% heat-inactivated fetal bovine serum (FBS), 100 µg/mL penicillin, 100 µg/mL streptomycin, 100 µg/mL amphotericin, and 3.7 g/L sodium bicarbonate. Culturing was conducted in a controlled environment at 37°C in a 5% CO₂ atmosphere. Harvesting of cells was performed when confluence reached 85 to 90%, and subsequent seeding after trypsin treatment was at a density of 1x10⁶ cells. For cell treatment with plant extract, a duration of 24 hours was employed. This protocol ensured the maintenance and treatment of NRK-52E cells under optimal conditions for experimental purposes.

NRK 52E Cell Treatment with Orthosiphon Stamineus Extracts

The experimental conditions involved the exposure of cells to various glucose concentrations and different concentrations of plant extract. The glucose concentrations tested included low glucose at 5.5 mM (1 g/L) and high glucose at 30 mM (4.5 g/L). In addition to these, cells were subjected to high glucose conditions of 30 mM (4.5 g/L) in combination with varying concentrations of plant extract, specifically 50 µg/ml, 100 µg/ml, 200 µg/ml, 300 µg/ml, and 400 µg/ml. These conditions aimed to assess the effects of different glucose levels and plant extract concentrations on cellular responses. Such controlled variations in glucose and extract concentrations allow for systematically investigating potential interactions and effects on cellular behaviour. This experimental design facilitates the exploration of potential therapeutic or detrimental impacts of the plant extract under different glucose environments, providing valuable insights into its potential utility in modulating cellular responses associated with glucose levels.
RNA isolation

RNA isolation was done from cells using TRIZOL reagent by standard lab protocol involving centrifugation (12,000×g) for 20 minutes at 4°C and precipitation by isopropanol. Nano drops RNA quantification done. The cDNA library was constructed with the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems).

Real-time PCR analysis

The real-time qPCR was conducted for SIRT1, HIF-1α, ET-1, and VEGFR-2 using the SYBR green qPCR mastermix (Takyon, Eurogentec).

HIF-1α:
Forward Primer: 5’GCCGCTGGAGACACAATCAT3’
Reverse Primer: 5’GAAGTGGCTTTGGCGTTTCA 3’

ET-1:
Forward Primer: 5’CAGGGCTGAAGACATTATGGAGA3’
Reverse Primer: 5’CATGGTCTCCGACCTGGTTT3’

VEGFR-2:
Forward Primer: 5’CGGACAGTGGTATGGTTCTTG3’,
Reverse Primer: 5’GTGGTGCTGTGTGTCATCGGATG3’

The PCR amplification was performed using the following thermal cycler program. Initial denaturation at 95°C for 3 minutes, denaturation 95°C for 10 seconds, primer annealing at 60°C for 20 seconds and extension at 72°C for 1 minute. The cycle threshold (CT) values obtained were analyzed by 2^−ΔΔCT formula.

Docking Study

The docking protocol utilized in this study involved the utilization of ligands obtained from the PubChem database, totaling 15 ligands. The protein structures utilized for the docking simulations included GSK-3b (PDB code: 6hk3) and Rho-kinase (PDB code: 2h9v), acquired from the RCSB Protein Data Bank. AutoDockVina served as the primary docking software, facilitating the computational docking simulations. These docking experiments were conducted using the PyRx platform, which provided a user-friendly interface for efficient setup and management of the docking runs. Additionally, for the visualization of hydrogen bond interactions between the ligands and the amino acid residues of the protein, the PYMOL software was employed, offering insights into potential binding modes and affinities at the molecular level.

Results

Quantitative expression analysis HIF-1α Gene

There was a 2.2794-fold increase in the expression of the HIF-1 gene when the cells were exposed to high glucose compared to those exposed to a normal glucose level. However, the expression of the HIF-1 gene decreased after treatment with different concentrations of plant extract in a dose-dependent manner up to 200 μg/ml. The decrease in the expression level was found to be in the range of 1.59–0.37 fold when the cells were treated with 50–200 plant extract. The lowest expression of the gene was observed in the cells treated with 200 μg/ml plant extract.

Table 1: Docking protocol

<table>
<thead>
<tr>
<th>Ligands</th>
<th>Downloaded from Pubchem site. 15 ligands</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protein structures</td>
<td>GSK-3b (6hk3), RHO-kinase (2h9v) downloaded from RCSB PDB (PW.Rose 2017)</td>
</tr>
<tr>
<td>Docking Software</td>
<td>AutoDock Vina (OT.Trott 2010)</td>
</tr>
<tr>
<td>Docking platform</td>
<td>PyRx</td>
</tr>
<tr>
<td>Amino-acid Hydrogen bond visualization platform</td>
<td>PYMOL (De Lano2002)</td>
</tr>
</tbody>
</table>

Figure 1. Expression of HIF-1α in NRK-52E treated with Orthosiphon stamineus plant extract under low and high glucose conditions. NG: normal glucose; HG: high glucose; 100, 200, 300, 400: concentration of plant extract in μg/ml
extract. The cells treated with 300 μg/ml of plant extract showed reduced expression (0.89±0.79) of the gene when compared to the control however was found to be relatively higher when compared to the cells treated with 200 μg/ml. At 400 μg/ml, the therapeutic benefit was lost and again the gene expression increased to glucotoxic levels (2.23±1.58).

**Quantitative expression analysis Endothelin-1 Gene**

![Figure 2. Expression of Endothelin-1 in NRK-52E treated with Orthosiphon stamineus plant extract under low and high glucose conditions. NG: normal glucose; HG: high glucose; 100, 200, 300, 400: concentration of plant extract in μg/ml.](image1)

The ET-1 gene expression was also found to be similar to the HIF-1α. There was a 5.64±5.34 fold increase in the expression of the ET-1 gene in the cells that were grown under the high glucose condition. Treatment with different concentrations of *Orthosiphon stamineus* extracts counteracted the increase in ET-1 expression in a dose-dependent manner, starting from 50 μg (4.64±3.83) to 200 μg/ml (0.70±0.37). The lowest gene expression level was observed with 200 μg/mL cells. At 300μg/ml, the expression was 1.91±0.81, still lower than hyperglycemia-induced elevation in gene expression. At 400 μg/ml, the therapeutic benefit was lost, and again, the gene expression increased to glucotoxic levels (5.38±2.98).

In the case of the VEGFR-2 gene, glucotoxicity decreased the gene expression levels compared to normoglycemia, and treatment with Orthosiphon extract did not show any consistent increase or decrease in gene expression levels. However, at concentrations above 100 μg/ml, there was a consistent reduction in VEGFR-2 gene expression up to 400 μg/ml.

**Docking Study Results**

![Figure 4. Molecular docking analysis of GSK-3b protein (6hk3) with staminol-D in the active G8B native ligand binding site.](image2)
Table 2. Docking score of phytochemicals found in the extract of *Orthosiphon stamineus* to GSK-3b protein (6hk3) structure

<table>
<thead>
<tr>
<th>Sl. No.</th>
<th>Ligands</th>
<th>Docking score with GSK-3B protein</th>
<th>Participating amino acid(s) of the protein</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Reference ligand</td>
<td>-8.4(G8B)</td>
<td>Ser-208, Ser-66</td>
</tr>
<tr>
<td>3</td>
<td>Norstaminol_B</td>
<td>-9.7</td>
<td>Lys-197</td>
</tr>
<tr>
<td>4</td>
<td>Orthosiphol_J</td>
<td>-12.1</td>
<td>Arg-141</td>
</tr>
<tr>
<td>5</td>
<td>Orthosiphol_M</td>
<td>-12.7</td>
<td>Arg-220, Ser-203</td>
</tr>
<tr>
<td>7</td>
<td>Orthosiphol_V</td>
<td>-11.3</td>
<td>Arg-220, Gln-185</td>
</tr>
<tr>
<td>8</td>
<td>Orthosiphol_Z</td>
<td>-9.4</td>
<td>Thr-253</td>
</tr>
<tr>
<td>10</td>
<td>Secoorthosiphol_B</td>
<td>-9.7</td>
<td>Arg-141, Arg-144</td>
</tr>
<tr>
<td>11</td>
<td>Secoorthosiphol_C</td>
<td>-9.7</td>
<td>Arg-220, Asp-200</td>
</tr>
<tr>
<td>12</td>
<td>Sinensetin</td>
<td>-6.4</td>
<td>Ser-203, Gln-185</td>
</tr>
<tr>
<td>13</td>
<td>Staminol_D</td>
<td>-9.7</td>
<td>Ser-203, Arg-220, Ser-219</td>
</tr>
<tr>
<td>14</td>
<td>Scuttelarein</td>
<td>-6</td>
<td>His-145, Arg-148, Arg-141</td>
</tr>
<tr>
<td>15</td>
<td>Vomifoliol</td>
<td>-6.5</td>
<td>Gly-65, Ser-66</td>
</tr>
</tbody>
</table>
Discussion

The gene expression studies show that Orthosiphon stamineus extracts counteracted the increase in HIF-1 expression in the dose range of 50μg/ml to 300 μg/ml. Similar action was also seen in the gene expression of endothelin-1. As far as we know, this is the first report on Orthosiphon stamineus extract reducing gene expression of HIF-1 and endothelin-1 in renal tubular cells. Further docking studies have shown that norstaminol_b, orthosiphol_j, orthosiphol_m, orthosiphol_v, orthosiphol_n, orthosiphol_z, staminol_d, secoorthosiphol_c, and secoort has a higher docking score compared to native ligands of the protein structures GSK-3b and Rho-kinase. Rho-kinase inhibition prevents the progression of diabetic nephropathy by downregulating hypoxia-inducible factor 1α (Matoba, 2009). As Orthosiphon phytochemicals show a good docking score, their binding may result in Rho-Kinase inhibition and, thereby down regulation of HIF-1α. As inhibition of GSK-3b can sometimes upregulate HIF-1α, the HIF-1α downregulation seen with Orthosiphon may be due to Rho-kinase binding and inhibition rather than via GSK-3b. In addition, due to its high docking score with GSK-3b, Orthosiphon can also have GSK-3b inhibitory activity, which may also be beneficial for the treatment of diabetic kidney disease. However, at higher concentrations, the benefits of the extract are lost, probably due to the direct toxicity of the extract.

Conclusion

Orthosiphon plant has multiple phytochemicals that influence the biochemical pathways involved in the pathogenesis of diabetic nephropathy, making it a promising treatment option for the disease. In conclusion, the comprehensive analysis of the Orthosiphon plant highlights its potential therapeutic efficacy in addressing diabetic nephropathy. The diverse array of phytochemicals found within Orthosiphon demonstrates a significant impact on the biochemical pathways implicated in the pathogenesis of the disease. This underscores the plant's promising role as a treatment option for diabetic nephropathy, offering avenues for further exploration and development in the field of natural medicine.

Conflict of Interest

The authors declare no conflict of interest.

Acknowledgement

The authors gratefully acknowledge the financial support provided by the Chettinad Academy of Research and Education (CARE SEED Funding) between 2016 and 2022. The authors acknowledge the Animal Tissue Culture Lab for the cell line work facility provided by the Department of Zoology, University of Madras. The authors also acknowledge the infrastructure support provided by the Department

Table 3. Docking score of phytochemicals found in the extract of Orthosiphon stamineus to Rho-kinase protein (2h9v)

<table>
<thead>
<tr>
<th>Sl. No.</th>
<th>Ligands</th>
<th>Docking score with Rho-kinase protein (2h9v)</th>
<th>Participating amino acid(s) of the protein</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Reference ligand</td>
<td>-6.3(Y27)</td>
<td>Asp-176, Asn-219, Asp-232</td>
</tr>
<tr>
<td>2</td>
<td>Ladanein</td>
<td>-6.6</td>
<td>Asn-179</td>
</tr>
<tr>
<td>3</td>
<td>Norstaminol_B</td>
<td>-11.4</td>
<td>Asn-179</td>
</tr>
<tr>
<td>4</td>
<td>Orthosiphol_J</td>
<td>-11.7</td>
<td>Asp-385</td>
</tr>
<tr>
<td>5</td>
<td>Orthosiphol_M</td>
<td>-10.4</td>
<td>Asp-385</td>
</tr>
<tr>
<td>7</td>
<td>Orthosiphol_V</td>
<td>-10.3</td>
<td>Asp-385</td>
</tr>
<tr>
<td>8</td>
<td>Orthosiphol_Z</td>
<td>-9.6</td>
<td>Thr-253</td>
</tr>
<tr>
<td>11</td>
<td>Secoorthosiphol_C</td>
<td>-10.8</td>
<td>Asp-385, Asp-386</td>
</tr>
<tr>
<td>13</td>
<td>Staminol_D</td>
<td>-10</td>
<td>Asp-385</td>
</tr>
<tr>
<td>15</td>
<td>Vomifoliol</td>
<td>-6.9</td>
<td>Asp-385, Ile-98</td>
</tr>
</tbody>
</table>
of Zoology at the University of Madras, established under the DST-FFIST program. The author acknowledges the infrastructure facilities provided at the Centre for Advanced Studies in Botany, University of Madras.

References


https://doi.org/10.1007/978-981-19-0027-3_6


https://doi.org/10.3389/fendo.2021.626390


https://doi.org/10.3390/jcm9020302


https://doi.org/10.1681/ASN.2005121355


https://doi.org/10.3109/10715762.2012.683431


https://doi.org/10.1007/s10495-014-1037-5


https://doi.org/10.52756/ijerr.2023.v32.032


https://doi.org/10.1016/S0026-0495(98)90314-6

https://doi.org/10.1038/sj.ki.5002567
https://doi.org/10.1186/s13020-022-00648-x
https://doi.org/10.3904/kjim.2012.27.2.163
https://doi.org/10.1016/j.phytol.2013.12.009
https://doi.org/10.1016/j.biopharma.2017.11.032
https://doi.org/10.1007/s11906-999-0077-7
https://doi.org/10.1016/j.biopharma.2018.06.055

How to cite this Article:
DOI :https://doi.org/10.52756/jerr.2024.v37sp015

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.